DR info

臨床試験数 : 14 / 薬物数 : 27 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 8

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Antipyretic
   Ultragenyx Pharmaceutical Inc
      2021   Phase 1/Phase 2   NCT04990388   Canada;France;Italy;Spain;United Kingdom;United States;
Carbohydrates intake
   University of British Columbia
      2017   -   NCT03218904   Canada;
Cornstarch
   Hospital de Clinicas de Porto Alegre
      2017   -   NCT03871673   Brazil;
Dexamethasone (or equivalent)
   ULTRAGENYX PHARMACEUTICAL INC.
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-IT   Canada;France;Germany;Italy;Spain;United Kingdom;United States;
EPHYNAL
   Dipartimento di Pediatria
      2006   -   EUCTR2006-005449-12-IT   Italy;
Empagliflozin
   Children's Memorial Health Institute, Poland
      2021   Phase 2   NCT04930627   Poland;
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2019   Phase 2   NCT04138251   Belgium;
Faxe Kondi Free
   Rigshospitalet, Denmark
      2015   -   NCT02448667   Denmark;
Glucose intake
   University of British Columbia
      2017   -   NCT03218904   Canada;
Glycosade
   John Mitchell
      2013   -   NCT02054832   Canada;
   University of Manitoba
      2014   -   NCT02176096   Canada;
H1 Blocker
   Ultragenyx Pharmaceutical Inc
      2021   Phase 1/Phase 2   NCT04990388   Canada;France;Italy;Spain;United Kingdom;United States;
H2 Blocker
   Ultragenyx Pharmaceutical Inc
      2021   Phase 1/Phase 2   NCT04990388   Canada;France;Italy;Spain;United Kingdom;United States;
MRNA che codifica l’enzima umano deramificante del glicogeno formulato in una nanopaticella lipidica
   ULTRAGENYX PHARMACEUTICAL INC.
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-IT   Canada;France;Germany;Italy;Spain;United Kingdom;United States;
MRNA encoding the human glycogen debranching enzyme formulated in a lipid nanoparticle delivery
   Ultragenyx Pharmaceutical Inc.
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-ES   Canada;France;Germany;Italy;Spain;United Kingdom;United States;
Ramipril
   Dipartimento di Pediatria
      2006   -   EUCTR2006-005449-12-IT   Italy;
Sweet polvilho
   Hospital de Clinicas de Porto Alegre
      2017   -   NCT03871673   Brazil;
Tocopherol (vit E)
   Dipartimento di Pediatria
      2006   -   EUCTR2006-005449-12-IT   Italy;
Triheptanoin
   Areeg El-Gharbawy
      2020   Early Phase 1   NCT03665636   United States;
   Baylor Research Institute
      2009   Phase 2   NCT00947960   France;United States;
UX007
   Copenhagen Neuromuscular Center
      2018   Phase 2   EUCTR2017-004153-17-DK   Denmark;
UX053
   ULTRAGENYX PHARMACEUTICAL INC.
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-IT   Canada;France;Germany;Italy;Spain;United Kingdom;United States;
   Ultragenyx Pharmaceutical Inc
      2021   Phase 1/Phase 2   NCT04990388   Canada;France;Italy;Spain;United Kingdom;United States;
   Ultragenyx Pharmaceutical Inc.
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-ES   Canada;France;Germany;Italy;Spain;United Kingdom;United States;